Daniel Sterman

Daniel Sterman

New York University

H-index: 58

North America-United States

About Daniel Sterman

Daniel Sterman, With an exceptional h-index of 58 and a recent h-index of 33 (since 2020), a distinguished researcher at New York University, specializes in the field of lung cancer, mesothelioma, tumor vaccines, gene therapy, immunotherapy.

His recent articles reflect a diverse array of research interests and contributions to the field:

Immune Tone of T Lymphocytes Within Tumor-draining Lymph Nodes of Advanced-stage Non-small Cell Lung Cancer Is Associated With Early Mortality

Lung Microbiota Influence Responses to Anti-PD1 Therapy in a Preclinical Model of Non-small Cell Lung Cancer

A Phase I Dose-escalation Clinical Trial of Bronchoscopic Cryoimmunotherapy

Longitudinal Analysis of Cytokine Profiles and Pulmonary Function in Post-acute Sequelae of SAR-CoV-2 (PASC) Patients

Spatial single-cell immune microenvironment analysis reveals the transition from innate to adaptive immune response during early lung adenocarcinoma carcinogenesis

Transcriptomic Signatures in Elderly Patients With Early-stage NSCLC Are Associated With Disease Recurrence

Onco-Pulmonology: Exploring a New Frontier in Pulmonary Medicine

Lower Airway Microbiome Signatures Associated With Clinical Outcomes in Non-Small Cell Lung Cancer Patients With Immunotherapy Treatment

Daniel Sterman Information

University

Position

Professor of Medicine and Cardiothoracic Surgery, NYU School of Medicine

Citations(all)

12062

Citations(since 2020)

4277

Cited By

9389

hIndex(all)

58

hIndex(since 2020)

33

i10Index(all)

107

i10Index(since 2020)

69

Email

University Profile Page

Google Scholar

Daniel Sterman Skills & Research Interests

lung cancer

mesothelioma

tumor vaccines

gene therapy

immunotherapy

Top articles of Daniel Sterman

Title

Journal

Author(s)

Publication Date

Immune Tone of T Lymphocytes Within Tumor-draining Lymph Nodes of Advanced-stage Non-small Cell Lung Cancer Is Associated With Early Mortality

B Kwok

BG Wu

IF Kocak

F Darawshy

I Laniado

...

2024/5

Lung Microbiota Influence Responses to Anti-PD1 Therapy in a Preclinical Model of Non-small Cell Lung Cancer

M Chang

C Mccormick

B Kwok

Y Li

Y Kyeremateng

...

2024/5

A Phase I Dose-escalation Clinical Trial of Bronchoscopic Cryoimmunotherapy

A Velez

I Laniado

R Schluger

A Demaio

V Murthy

...

2024/5

Longitudinal Analysis of Cytokine Profiles and Pulmonary Function in Post-acute Sequelae of SAR-CoV-2 (PASC) Patients

BV Garimella

D Collazo

S Basdeo

J Cirillo

S Shankar

...

2024/5

Spatial single-cell immune microenvironment analysis reveals the transition from innate to adaptive immune response during early lung adenocarcinoma carcinogenesis

Cancer Research

Bo Zhu

Pingjun Chen

Muhammad Aminu

Junya Fujimoto

Lingzhi Hong

...

2024/3/22

Transcriptomic Signatures in Elderly Patients With Early-stage NSCLC Are Associated With Disease Recurrence

F Darawshy

JJ Tsay

I Sulaiman

B Kwok

K Wong

...

2024/5

Onco-Pulmonology: Exploring a New Frontier in Pulmonary Medicine

Isaac Laniado

Antonio Velez

Daniel H Sterman

2024/2/21

Lower Airway Microbiome Signatures Associated With Clinical Outcomes in Non-Small Cell Lung Cancer Patients With Immunotherapy Treatment

F Darawshy

JJ Tsay

I Sulaiman

A Lukovnikova

K Krolikowski

...

2024/5

Elevated Derived Neutrophil-to-Lymphocyte Ratio Is Associated With Lower Airway Dysbiosis in Non-Small Cell Lung Cancer

MS Dreier

B Kwok

IF Kocak

R Schluger

Y Li

...

2023/5

Cryoablation and immunity in non-small cell lung cancer: a new era of cryo-immunotherapy

Antonio Velez

Andrew DeMaio

Daniel Sterman

2023/8/21

Pathomic Features Reveal Immune and Molecular Evolution from Lung Preneoplasia to Invasive Adenocarcinoma

Modern Pathology

Pingjun Chen

Frank R Rojas

Xin Hu

Alejandra Serrano

Bo Zhu

...

2023/12/1

Immune Tone of Tumor-draining Lymph Nodes in Non-small Cell Lung Cancer

B Kwok

BG Wu

IF Kocak

I Laniado

F Darawshy

...

2023/5

CAN-2409 plus prodrug with standard of care immune checkpoint inhibitor for patients with stage III/IV NSCLC.

Charu Aggarwal

Daniel Sterman

Fabien Maldonado

Christine M Bestvina

Janani S Reisenauer

...

2023/6/1

Inflammation in the tumor-adjacent lung as a predictor of clinical outcome in lung adenocarcinoma

Nature Communications

Igor Dolgalev

Hua Zhou

Nina Murrell

Hortense Le

Theodore Sakellaropoulos

...

2023/11/8

Pleural fluid microbiota as a biomarker for malignancy and prognosis

Scientific Reports

Benjamin Kwok

Benjamin G Wu

Ibrahim F Kocak

Imran Sulaiman

Rosemary Schluger

...

2023/2/8

Role of small airway dysfunction in unexplained exertional dyspnoea

ERJ Open Research

Alexis L Sharpe

Joan Reibman

Beno W Oppenheimer

Roberta M Goldring

Mengling Liu

...

2023/5/1

SAFETY RESULTS FROM MULTI-CENTER OBSERVATIONAL REAL-WORLD ROBOTIC BRONCHOCOPY (TARGET) STUDY

CHEST

SEPTIMIU D MURGU

Alexander C Chen

Jaime Connelly

Daniel H Sterman

Kazuhiro Yasufuku

...

2023/10/1

Transcriptomic Signature of Acute VTE Associated With SARS-CoV-2 Infection; Single Center Retrospective Observational Study

SB Brosnahan

CR Barnett

I Sulaiman

M Chung

LF Angel

...

2023/5

IMPACTS ON MANAGEMENT OF HIGH-RISK LUNG NODULES AND PATIENT OUTCOMES AFTER VIRTUAL REVIEW BY A MULTIDISCIPLINARY LUNG NODULE REVIEW BOARD

Keshav Mangalick

Hugh J Remar

Rachel Nelson

Maria Banvard

Karen Alisa Braithwaite

...

2023/10/1

PULMONARY TUBERCULOSIS OR ORGANIZING PNEUMONIA: A CASE OF EMPIRIC TREATMENT FOR THE WRONG DISEASE

CHEST

Keshav Mangalick

Nalinee Srisarajivakul-Klein

Jasmine Corona

Caralee E Caplan-Shaw

Daniel H Sterman

2023/10/1

See List of Professors in Daniel Sterman University(New York University)